Vi­a­tris and Mapi eval­u­ate next steps af­ter FDA re­jects long-act­ing MS in­jec­tion

The FDA hand­ed down a com­plete re­sponse let­ter to Vi­a­tris and Mapi Phar­ma for their long-act­ing in­jec­tion for the treat­ment of re­laps­ing forms of mul­ti­ple scle­ro­sis, the com­pa­nies an­nounced Mon­day.

In a state­ment with few de­tails, the com­pa­nies said they are re­view­ing the CRL and will be “de­ter­min­ing the ap­pro­pri­ate next steps,” adding that they “con­tin­ue to be­lieve in the po­ten­tial of the prod­uct to pro­vide an im­por­tant new treat­ment ad­vance­ment for pa­tients with mul­ti­ple scle­ro­sis.” Vi­a­tris said that the re­jec­tion doesn’t change its 2024 fi­nan­cial guid­ance or its new prod­uct rev­enue range of $450 mil­lion to $550 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER